Hypoxia promotes stem-like properties of laryngeal cancer cell lines by increasing the CD133+ stem cell fraction

International Journal of Oncology

Volumn 44, Issue 5, 2014, Pages 1652-1660

  Wu, Chun Ping ^a   Du, Huai Dong ^a   Gong, Hong L I ^a   Li, D A Wei ^a   Tao, Lei ^a   Tian, Jie ^a   Zhou, Liang ^a  

^a EYE AND ENT HOSPITAL OF FUDAN UNIVERSITY   (China)

Author keywords

Cell biology; Hypoxia; Hypoxia inducible factors; Laryngeal neoplasm; Neoplastic stem cells; Tumor microenvironment

Indexed keywords

CD133 ANTIGEN; HYPOXIA INDUCIBLE FACTOR; OCTAMER TRANSCRIPTION FACTOR 4; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2;

ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL CYCLE G0 PHASE; CELL INVASION; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; HUMAN; HUMAN CELL; HYPOXIA; LARYNX CANCER; PRIORITY JOURNAL; STEM CELL;

ANTIGENS, CD; CELL CYCLE; CELL HYPOXIA; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; HUMANS; LARYNGEAL NEOPLASMS; NEOPLASM PROTEINS; NEOPLASTIC STEM CELLS; PEPTIDES; TUMOR MARKERS, BIOLOGICAL;

EID: 84899094214     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2307     Document Type: Article

References (38)

1. Visvader JE and Lindeman GJ: Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 8: 755-768, 2008.
2. Akhtar K, Bussen W and Scott SP: Cancer stem cells - from initiation to elimination, how far have we reached? (Review). Int J Oncol 34: 1491-1503, 2009.
3. Bhaijee F, Pepper DJ, Pitman KT and Bell D: Cancer stem cells in head and neck squamous cell carcinoma: a review of current knowledge and future applications. Head Neck 34: 894-899, 2012.
4. Sneddon JB and Werb Z: Location, location, location: the cancer stem cell niche. Cell Stem Cell 1: 607-611, 2007. (Pubitemid 350215340)
5. Borovski T, De Sousa E Melo F, Vermeulen L and Medema JP: Cancer stem cell niche: the place to be. Cancer Res 71: 634-639, 2011.
6. Takakura N: Formation and regulation of the cancer stem cell niche. Cancer Sci 103: 1177-1181, 2012.
7. Keith B and Simon MC: Hypoxia-inducible factors, stem cells, and cancer. Cell 129: 465-472, 2007. (Pubitemid 46660978)
8. Sun QJ, Li XM, Lu XY and Di B: Cancer stem cells may be mostly maintained by fluctuating hypoxia. Med Hypotheses 76: 471-473, 2011.
9. Lin Q and Yun Z: Impact of the hypoxic tumor microenvironment on the regulation of cancer stem cell characteristics. Cancer Biol Ther 9: 949-956, 2010.
10. Hill RP, Marie-Egyptienne DT and Hedley DW: Cancer stem cells, hypoxia and metastasis. Semin Radiat Oncol 19: 106-111, 2009.
11. Conley SJ, Gheordunescu E, Kakarala P, et al: Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc Natl Acad Sci USA 109: 2784-2789, 2012.
12. Ma YY, Liang DM, Liu J, et al: Prostate cancer cell lines under hypoxia exhibit greater stem-like properties. PLoS One 6: e29170, 2011.
13. Liang DM, Ma YY, Liu J, Trope CG, Holm R, Nesland JM and Suo ZH: The hypoxic microenvironment upgrades stem-like properties of ovarian cancer cells. BMC Cancer 12: 201, 2012.
14. Li PC, Zhou C, Xu LS and Xiao HL: Hypoxia enhances stemness of cancer stem cells in glioblastoma: an in vitro study. Int J Med Sci 10: 399-407, 2013.
15. Zhou L, Wei XD, Cheng L, Tian J and Jiang JJ: CD133, one of the markers of cancer stem cells in Hep-2 cell line. Laryngoscope 117: 455-460, 2007. (Pubitemid 46407753)
16. Wei XD, Zhou L, Cheng L, Tian J, Jiang JJ and MacCallum J: In vivo investigation of CD133 as a putative marker of cancer stem cells in Hep-2 cell line. Head Neck 31: 94-101, 2009.
17. Chen H, Zhou L, Dou TH, Wan GL, Tang HQ and Tian J: BMI1's maintenance of the proliferative capacity of laryngeal cancer stem cells Head Neck 33: 1115-1125, 2011.
18. Guppy M: The hypoxic core: a possible answer to the cancer paradox. Biochem Biophys Res Commun 299: 676-680, 2002.
19. Tsujinaka S, Soda K, Kano Y and Konishi F: Spermine accelerates hypoxia-initiated cancer cell migration. Int J Oncol 38: 305-312, 2011.
20. Clevers H: The cancer stem cell: premises, promises and challenges. Nat Med 17: 313-319, 2011.
21. Yoshiba S, Ito D, Nagumo T, Shirota T, Hatori M and Shintani S: Hypoxia induces resistance to 5-fluorouracil in oral cancer cells via G(1) phase cell cycle arrest. Oral Oncol 45: 109-115, 2009.
22. Box AH and Demetrick DJ: Cell cycle kinase inhibitor expression and hypoxia-induced cell cycle arrest in human cancer cell lines. Carcinogenesis 25: 2325-2335, 2004. (Pubitemid 39625172)
23. Hashimoto O, Shimizu K, Semba S, Chiba S, Ku Y, Yokozaki H and Hori Y: Hypoxia induces tumor aggressiveness and the expansion of CD133-positive cells in a hypoxia-inducible factor-1alpha-dependent manner in pancreatic cancer cells. Pathobiology 78: 181-192, 2011.
24. Soeda A, Park M, Lee D, et al: Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha. Oncogene 28: 3949-3959, 2009.
25. Shi G and Jin Y: Role of Oct4 in maintaining and regaining stem cell pluripotency. Stem Cell Res Ther 1: 39, 2010.
26. Schmidt R and Plath K: The roles of the reprogramming factors Oct4, Sox2 and Klf4 in resetting the somatic cell epigenome during induced pluripotent stem cell generation. Genome Biol 13: 251, 2012.
27. Luo W, Li S, Peng B, Ye Y, Deng X and Yao K: Embryonic stem cells markers SOX2, OCT4 and Nanog expression and their correlations with epithelial-mesenchymal transition in nasopharyngeal carcinoma. PLoS One 8: e56324, 2013.
28. Takahashi K and Yamanaka S: Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126: 663-676, 2006. (Pubitemid 44233629)
29. Huangfu D, Osafune K, Maehr R, et al: Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. Nat Biotechnol 26: 1269-1275, 2008.
30. Kolenda J, Jensen SS, Aaberg-Jessen C, Christensen K, Andersen C, Brunner N and Kristensen BW: Effects of hypoxia on expression of a panel of stem cell and chemoresistance markers in glioblastoma-derived spheroids. J Neurooncol 103: 43-58, 2011.
31. Iida H, Suzuki M, Goitsuka R and Ueno H: Hypoxia induces CD133 expression in human lung cancer cells by up-regulation of OCT3/4 and SOX2. Int J Oncol 40: 71-79, 2012.
32. Covello KL, Kehler J, Yu H, et al: HIF-2alpha regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth. Genes Dev 20: 557-570, 2006. (Pubitemid 43345322)
33. Mathieu J, Zhang Z, Zhou W, et al: HIF induces human embryonic stem cell markers in cancer cells. Cancer Res 71: 4640-4652, 2011.
34. Li DW, Zhou L, Jin B, Xie J and Dong P: Expression and significance of hypoxia-inducible factor-1alpha and survivin in laryngeal carcinoma tissue and cells. Otolaryngol Head Neck Surg 148: 75-81, 2013.
35. Pietras A, Hansford LM, Johnsson AS, et al: HIF-2alpha maintains an undifferentiated state in neural crest-like human neuroblastoma tumor-initiating cells. Proc Natl Acad Sci USA 106: 16805-16810, 2009.
36. Sun HC, Qiu ZJ, Liu J, et al: Expression of hypoxia-inducible factor-1α and associated proteins in pancreatic ductal adenocarcinoma and their impact on prognosis. Int J Oncol 30: 1359-1367, 2007.
37. Jubb AM, Buffa FM and Harris AL: Assessment of tumour hypoxia for prediction of response to therapy and cancer prognosis. J Cell Mol Med 14: 18-29, 2010.
38. Lundgren K, Holm C and Landberg G: Hypoxia and breast cancer: prognostic and therapeutic implications. Cell Mol Life Sci 64: 3233-3247, 2007.